Roundtable discussion about caffeine and physical performance

July 06, 2017

"Through the use of the Presage ST2 Assay, clinicians can assess patient prognosis with the hope of being able to better personalize care," says Snider.

"ST2 is a very important advance in our ability to provide accurate prognostic information for patients diagnosed with chronic heart failure," states G. Michael Felker, MD, MHS, Associate Professor of Medicine, Division of Cardiology, Duke University School of Medicine. "In the future, there is hope that a better understanding of prognosis using markers like ST2 can help us guide therapy and ultimately improve outcomes in heart failure patients."

"This latest regulatory milestone follows the granting earlier this year of a CE (Conformit?© Europ?©enne) Mark in Europe," says David Geliebter, Chairman of Critical Diagnostics. "We are very gratified that the Presage ST2 Assay is now available to assist critically-ill heart failure patients in both Europe and the United States."

Source: Critical Diagnostics